Aankondiging • Jun 21
Light AI Inc. announced that it has received CAD 5 million in funding On June 19, 2026, Light AI Inc. closed the transaction. Aankondiging • Jun 16
Light Ai Announces Company-Funded Field Study for Quickscan Strep A Platform in New Zealand Light AI Inc. announced a company-funded field study in New Zealand for the deployment and evaluation of the Company's QuickScan Strep A software platform in community and school-based healthcare settings. The field study is being conducted in collaboration with New Zealand healthcare stakeholders, including the National Hauora Coalition, and is designed to evaluate real-world implementation, workflow integration, accessibility, and commercial readiness of Light AI's QuickScan Strep A software application for point-of-care screening and clinical decision support relating to pharyngitis and suspected Group A Streptococcus infections. In pre-FDA validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus. The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease, which imposes a global economic burden exceeding $1 trillion annually. Light AI QuickScan is a technology platform which represents the next generation of patient management: it applies AI algorithms to compatible smart device images, starting with images of Strep A and anticipated expansion with other medical conditions, to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind as its computing platform includes the 4.5 billion smartphones that exist in the world today. Aankondiging • Jun 04
Light AI Initiates FDA Pivotal Clinical Trial for QuickScan Strep a Software as a Medical Device Light AI Inc. has received ethics committee approval to commence the pivotal clinical trial intended to generate clinical evidence to support a future submission to the U.S. Food and Drug Administration for potential marketing authorization of QuickScan Strep A as a Class II medical device. The study protocol and design are informed by prior regulatory interactions, including pre-submission feedback received by the Company during its 2024 FDA Q-Sub process. QuickScan Strep A is being developed as a smartphone-enabled software platform intended to analyze throat images and provide an AI-supported assessment for suspected Strep A infection. The software remains investigational and has not been cleared or approved by the FDA or other regulatory authorities for commercial diagnostic use. The pivotal study is expected to enroll participants presenting with symptoms consistent with pharyngitis and is designed to compare the diagnostic performance of QuickScan Strep A against throat culture, an established clinical reference standard. Predefined study endpoints include diagnostic outcome measures, usability assessments, and patient management-related measures intended to support evaluation of software performance and a future FDA submission. Strep A pharyngitis is a common condition evaluated across primary care, urgent care, pediatric, pharmacy and community healthcare settings. Subject to successful clinical validation, regulatory authorization and commercial adoption, Light AI believes there may be future opportunities for software-enabled assessment technologies to support healthcare delivery and patient management pathways. The Company expects to provide updates regarding study progress, enrollment milestones, and timing considerations as appropriate and in accordance with applicable securities disclosure obligations. Aankondiging • Jun 02
Light AI Inc., Annual General Meeting, Jul 22, 2026 Light AI Inc., Annual General Meeting, Jul 22, 2026. Location: british columbia, vancouver Canada Aankondiging • May 22
Light AI Inc. announced that it expects to receive CAD 5 million in funding Light AI Inc. announced a private placement with MV Capital LP to issue 5,000 secured convertible debenture units at an issue price of CAD 1,000 for the proceeds of CAD 5,000,000 on May 21, 2026. Each Unit will comprise of (i) a 12.0% secured convertible debenture of the Company in the principal amount equal to CAD 1,000 (each, a "Convertible Debenture") with interest compounded quarterly and payable on the earlier of the Maturity Date (as defined hereafter), prepayment or conversion and maturing 24 months from the closing of the Financing (the "Maturity Date"), and (ii) 8,000 common share purchase warrants (each, a "Warrant"), each Warrant being exercisable for a period of 36 months following the closing of the Financing (the "Closing Date") to purchase one common share of the Company (each, a "Warrant Share") at an exercise price of CAD 0.25 per Warrant Share. The Financing is expected to close on or around June 19, 2026, and is subject to certain closing conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Exchange. Board Change • May 21
Less than half of directors are independent There are 9 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Emmanuel Blin is the most experienced director on the board, commencing their role in 2024. Independent Chairman Steve Semmelmayer was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Aankondiging • Dec 05
Light AI Inc. Announces Transition Of Anthony Schaller From President And Chief Technology Officer To Advisory Role Light AI Inc. announced that the Company's President and Chief Technology Officer, Mr. Anthony Schaller, has transitioned from the Company's President and Chief Technology Officer to an advisory role. Mr. Schaller has been instrumental in leading the Company's product development initiatives since late 2024 culminating with the Company's first version of its commercially oriented software completion. The Company is now transitioning to focus on its regulatory and commercialization initiatives. Aankondiging • Nov 19
Light AI Inc. Announces the Completion of Version 1.0 of its Commercial Software Platform Light AI Inc. announced the completion of Version 1.0 of its commercial software platform. The software leverages proprietary AI algorithms to analyze smartphone images--initially focused on detecting Group A Streptococcus ("Strep A")--delivering rapid, accurate results without the need for swabs or lab tests. The app-based solution is designed for use on both iOS and Android devices, enabling broad accessibility and scalability. Light AI plans to initiate a pilot study with a major global healthcare provider to confirm the performance in managing pharyngitis cases in a real-world clinical urgent care medical setting. The pilot is expected to pave the way for initial anticipated commercial distribution and global expansion. Beyond pharyngitis, Light AI's platform is designed to expand into other diagnostic areas, including eye and skin conditions. The Company's broader vision is to create a cloud-based "Digital Clinical Lab" that transforms smartphones into accessible diagnostic tools, reducing reliance on traditional lab infrastructure. Aankondiging • Oct 22
Light AI Inc. Announces Board Changes Light AI Inc. announced the appointment of two new directors to its board of directors, Mr. Robert Cartagena and Mr. Mario Vetro. Robert Cartagena is co-founder and managing partner of Mill Street Equity Partners LLC (formerly Mill Street Partners LLC), a specialty investment strategy development firm focused on middle-market dental and medical device companies. Robert had a 33-year career as a C-level executive and or board member for various dental manufacturing companies including Discus Dental LLC and DenMat Holdings LLC, serving as Chief Operating Officer for each firm. At both companies Robert led the development and launch of products which are now household brands in the dental industry in product categories such as surgical lasers, dental materials, professional teeth whitening, magnification and more. He has created tremendous value at various companies through new product development, sales and marketing, as well as buy-side and sell-side M&A in both private and public environments. Mario Vetro brings substantial expertise in structuring and raising capital for growth companies with a focus on technology and the natural resources sector. He currently serves as CEO of Commodity Partners Inc, a boutique merchant bank and advisory firm. There, he played a pivotal role in the co-founding of K92 Mining Inc., a company listed on the TSX, leading to the establishment of a world-class gold discovery and mining operation in Papua New Guinea. Building upon this success, Mr. Vetro excels at assembling formidable leadership teams, securing equity capital, and devising strong business strategies. The Company also announced the Mr. Hugh Cleland is transitioning from the Company's Board of Directors due to health reasons. Mr. Cleland has been instrumental in the Company's transition to a public company and supporting the Company in its financing and investor relations initiatives. Aankondiging • Sep 05
Light AI Inc. Announces Transition of Thomas Scarnecchia from Chief Operating Officer to an Advisory Role, Effective September 1, 2025 Light AI Inc. announced the transition of its Chief Operating Officer ("COO"), Thomas Scarnecchia, to an advisory role primarily supporting the Company's regulatory initiatives effective September 1, 2025. Aankondiging • Jul 08
Light Ai Inc. Achieves Key Internal Milestones in the Development of Its Wellness Strep A Screening Application Light AI Inc. announced that it has achieved key internal milestones in the development of its Wellness Strep A screening application. The Company's AI powered software platform is currently undergoing internal user testing by Light AI and its low and middle income countries go-to-market partner, Tech Care For All. The Company continues to progress with its initial commercialization efforts for its Wellness Application, inclusive of potential targeted market-demonstration deployments with pharmacy companies. Commercial availability of the Company's Wellness Application remains targeted for late 2025. The global AI healthcare market is projected to reach USD 110.6 billion by 2030 from USD 21.7 billion in 2025, at a CAGR of approximately 39% based upon adoption to new AI health and wellness solutions. The market is anticipated to grow due to the growing investments & funding by public-private organizations, the fast proliferation of AI in the healthcare industry, and the rising focus on developing human-aware AI systems. The market is experiencing growth due to increasing demand for enhanced services due to an unequal ratio between the healthcare workforce and patient numbers. However, inadequate IT infrastructure and inability to adopt AI-based healthcare solutions in emerging economies are estimated to pose a challenge to market growth to be addressed. Aankondiging • May 02
Light AI Inc. Moves Forward on Third 2025 Wellness Commercialization Plan Light AI Inc. announced that it continues to make solid progress towards its Wellness App Third Quarter 2025 commercialization consistent with the Company's prior announcement. Progress is being made on the Wellness App's innovative and intuitive UI design which will provide a seamless and empowering user experience. The Company anticipates showcasing a closed demo of its Wellness App within approximately 90 days to support its pre-commercialization initiatives. Built with experienced oversight and cutting-edge design principles at its core the AI oriented UI offers a seamless, beautifully easy to use navigation experience. Every touchpoint has been designed, reviewed, debated and engineered to make it easy for users to indicate their symptoms of concern, move to a scan, and quickly receive feedback with recommended next steps. Highlights of the Wellness App UI include: Streamlined Navigation - Clear map of the journey along with simplified menus create an experience easy for users to navigate; Cross-platform consistency - Whether users are on an IOS or Android device, the experience remains consistent and engaging; Personalized History and Resources - Users can see prior results and build a baseline of scan results, healthy or in response to reported symptoms; and Vibrant, Engaging Intuitive Visuals - The vibrant colour palette and typography promote a sense of calm, engagement and positivity. The innovative and intuitive UI design will roll out to users in a staggered release to allow time for feedback and improvement before full commercial launch anticipated in late 2025. Aankondiging • Apr 17
Light AI Inc. Auditor Raises 'Going Concern' Doubt Light AI Inc. filed its Annual on Apr 15, 2025 for the period ending Dec 31, 2024. In this report its auditor, SHIM & Associates LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Aankondiging • Apr 16
Light AI Inc. Announces Expansion of Its Wellness Platform Light AI Inc. announced that its innovative wellness platform, anticipated to launch in Third Quarter of 2025, is expanding its capabilities to help users rule out COVID-19 and conjunctivitis (pink eye) in addition to Strep A. The wellness platform is a direct-to-consumer product designed to support the quick detection and management of these conditions and will serve as a cornerstone in Light AI's expanding suite of healthcare tools aimed at supporting millions of families and individuals worldwide. These additional medical conditions expand Light AI's addressable market and are anticipated to enhance revenue and opportunities for licensing and partnership. This illustrates the Company's progress toward its ultimate goal of being a one-stop application to enhance health and wellness. Group A Strep, a common yet potentially serious infection, can cause significant health complications if not managed properly. Light AI's app will leverage advanced machine learning (ML) algorithms to provide accurate and timely diagnosis, empowering families to manage this condition more effectively. Conjunctivitis is a highly infectious condition affecting approximately 6 million people annually in the USA alone, and can lead to severe complications such as cellulitis, orbital cellulitis, keratitis, corneal ulcers, and scarring, potentially increasing the risk of permanent vision impairment if left untreated. Light AI's dedicated team is currently working to advance diagnostics on healthcare issues and will provide updates as new algorithms are refined. This expanded ecosystem will not only provide economies of scale to support market demand but will also generate valuable data to enhance predictive algorithms for future healthcare solutions. Aankondiging • Apr 01
Light Ai Inc. Appoints Anthony Schaller as President and CTO Light AI Inc. announce the appointment of Anthony Schaller as the new President and CTO. Mr. Schaller is a globally recognized leader in the technology industry. Since October 2024, Mr. Schaller has been assessing and planning Light AI's app platform and cloud-based development activities, driving Light AI's technology road map and related commercialization initiatives. Four Decades Of Development Experience Mr. Schaller has four decades of extensive experience in global strategy, innovation, research and development, and product and technology development and commercialization across enterprise and consumer markets in North America including: Creating and implementing the platform for digital media distribution to portable music devices as well as in the home, inclusive of the MPEG-1 Audio Layer 3 (MP3) player and Advanced Audio Coding (AAC) industry file format to compress and store audio; Leading technology innovation and transformation efforts at CitySearch /Ticketmaster; Leader in chemical R&D solving the problem of database access in different formats and systems enabling global pharmaceutical researchers to accelerate drug discovery; Led pioneering development of distributed databases and file systems starting with the Andrew Project at Carnegie Mellon University (CMU) and Ingres; Led technology scale-up and commercialization of Match.com (pioneer internet-based dating site), responsible for approximately 40x increase in user traffic and a 10x increased market capitalization, resulting in a buyout; and Senior Operating advisor for a global private equity firm with over $60 billion in assets under management providing operational strategy, SaaS transformation of process and products, margin efficiency /improvement leadership as well as due diligence on strategic acquisitions. Aankondiging • Feb 06
Light AI Inc. Announces Appointments to Advisory Board Light AI Inc. announced its Advisory Board. The Advisory Board has been designed to accelerate Light AI's goal of becoming a leader in the global AI healthcare market and will provide oversight and strategic guidance, advise on go-to-market strategies, and collaborate closely with the Company's leadership team and board of directors (the "Board"). The distinguished members of Light AI's Advisory Board include: Yu Zhao Yu Zhao is the President of Bridging Consulting LLC, a boutique regulatory firm supporting AI startups and medical device companies. With 16 years of leadership experience at Medtronic, including roles as Director and Interim VP of Regulatory Affairs, Mr. Zhao offers expert insights into navigating complex regulatory landscapes. Over the course of his career, Mr. Zhao and his teams have secured more than 150 U.S. FDA approvals and clearances, spanning PMAs, PMA supplements, IDEs, 510(k)s, and De Novos, for a wide range of devices—from implantable devices to deep learning algorithms. Raymond Ng Raymond Ng is a Professor of Computer Science at the University of British Columbia and the Director of the Data Science Institute. Mr. Ng is a recognized authority in Machine Learning and Data Science, contributing invaluable expertise to the advisory committee. He has published over 250 refereed articles on diverse topics related to data science. He is the Canada Research Chair on data science and analytics, and an elected fellow of the Royal Society of Canada. For both 2022 and 2023, he was named one of the world's top-75 academic data science leaders by the MIT-based CDO magazine. David Talan Dr. David A. Talan is board-certified in Internal Medicine, Emergency Medicine, and Infectious Diseases, and serves as Professor of Medicine in Residence (Emeritus) at UCLA and the University of Iowa. He has chaired the Olive View-UCLA Department of Emergency Medicine and is currently on the faculty at UCLA Ronald Reagan Medical Center. Dr. Talan's research focuses on acute infections, emergency department-based surveillance, and epidemiological research of emerging infections. He has numerous publications in prestigious journals, and his work has significantly influenced the management of infectious diseases. David Bell David Bell is a public health physician and expert in infectious disease diagnostics. Formerly leading malaria diagnostics coordination at the WHO, Programme Head of Malaria & Acute Febrile Disease at the Foundation for Innovative New Diagnostics (FIND), and Director of Global Health Technologies at Intellectual Ventures Global Good Fund, he now consults in global health and biotech, driving impactful solutions in global health. Aankondiging • Jan 28
Light AI Inc. Announces the Appointment of George Reznik to Corporate Secretary Light AI Inc. announced the appointment of George Reznik to Corporate Secretary effective January 27, 2025. Mr. Reznik has extensive expertise in international corporate finance, strategic business planning, mergers and acquisitions, business restructuring and growth management, investor relations, and operational management. Mr. Reznik is formerly the CFO of Tantalus Systems. Prior to joining Tantalus, Reznik was CFO and Corporate Secretary of Intrinsyc Technologies until its successful acquisition by Lantronix, CFO of DDS Wireless, CFO and COO of Infowave Software, and the Vice President of Finance at Pivotal Corporation where he played a leadership role through its IPO on the Nasdaq and its subsequent rapid business and revenue growth from USD 10 million to over USD 140 million over a three year period. Mr. Reznik previously was the Corporate Finance Valuation Practice Leader of Deloitte based in Canada and the UK. Mr. Reznik is a Chartered Professional Accountant - Chartered Accountant (CPA, CA), a Chartered Business Valuator (CBV), a Certified Fraud Examiner (CFE) and holds a Bachelor of Commerce (Honors) degree from the University of Manitoba. He is the Chair of the BC Hi Tech CFO C-Council and was the recipient of the BC Public Company CFO of the Year award. 
